Abstract:Objective: Mel-18 is a member of the polycomb group (PcG) of proteins, which are chromatin retaliatory factors that play an important role in development and oncogenesis. This study was designed to investigate the clinical and prognostic significance of Mel-18 in the patients with prostate cancer. Patients and methods: Immunostaining with Mel-18 specific antibodies was performed on paraffin sections from 202 patients. Correlations between Mel-18 and the Gleason grading system, clinical stage, serum prostate-specific antigen (PSA) levels, and age were evaluated. PSA recurrence in 76 patients who underwent radical prostatectomy and survival in 59 patients with metastases at diagnosis were analyzed to evaluate the influence of Mel-18 expression in cancer progression using Kaplan-Meier analysis and multivariate Cox regression analysis. Results: Staining was seen in all prostatic tissues. Mel-18 expression was significantly reduced in the prostate cancer patients with PSA levels over 100 ng/ml (P = 0.009), advanced clinical stage (>T4, N1, or M1 disease, P = 0.029), higher Gleason grade or with a higher Gleason score (P = 0.018) than in those with other clinicopathologic features. Negative expression of Mel-18 was associated with significantly higher rates of PSA recurrence after radical prostatectomy than with positive expression of Mel-18 (P = 0.029), and was an independent predictor of PSA recurrence (P = 0.034, HR = 2.143) in multivariate analysis. Similarly, metastatic prostate cancer patients with negative expression of Mel-18 showed significantly worse survival compared with the positive expression of Mel-18 (P = 0.025). In multivariate analysis, negative expression of Mel-18 was an independent predictor of cancer-specific survival (P = 0.024, HR = 2.365). Conclusion: Our study provides important evidence for the recognition of Mel-18 as a tumor suppressor. The expression of Mel-18 showed potential as a prognostic marker for human prostate cancer. (C) 2011 Elsevier Inc. All rights reserved.

Expression of p19 in human testicular cancer

[Expression of Human Testis Development Related Gene 1 in Testicular Cancer Detected by Tissue Microarray].

The Expressions of P-gp and P38 Protein in Human Hepatocellular Carcinoma

Unique expression patterns of H19 in human testicular cancers of different etiology

Expression of Med-19 in bladder urothelial carcinoma and its clinical significance

Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients.

Differences in cytochrome P4502C19 (CYP2C19) expression in adjacent normal and tumor tissues in chinese cancer patients

The expression of 53 in cervical carcinoma

The Expression and Importance of P53 Protein in Colorectal Carcinoma

Histochemical Analysis of Testis Specific Gene 13 in Human Normal and Malignant Tissues

The Expression of Cytokeratin 19mrna and Its Clinical Significance in Bladder Carcinomas

The Expression of p16 and p53 Tumor Suppressor Gene in Bladder Carcinoma

Human Testis-Expressed Sequence 101 is Limitedly Distributed in Germinal Epithelium of Testis and Disappears in Seminoma

Tumour-suppressor Activity of H19 RNA

Analysis of Mel-18 Expression in Prostate Cancer Tissues and Correlation with Clinicopathologic Features.

Expression of Med19 in bladder cancer tissues and its role on bladder cancer cell growth.

C-myc Protein Expression in Human Testicular Tumors

RNA Silencing Suppressor P19 Regulates the Expressions of Cell Cycle Related Genes

Clinical Significance of H 19 As a Prognostic Factor in Human Cancer : a Systematic Review and Meta-Analysis

Scanning of novel cancer/testis proteins by human testis proteomic analysis.

CMTM2 expression in human testicular cancer tissues by tissue microarray analysis